Size | Price | |
---|---|---|
100mg | ||
250mg | ||
500mg | ||
Other Sizes |
ln Vitro |
In hEP2-HEK293/EBNA cells, butaprost (1-100 nM; 0.5-24 hours) causes a dose- and time-dependent elevation of Nur77 mRNA expression of approximately five times. By activating the PKC pathway, butaprost increased the expression of the Nur77 gene[1]. In Madin-Darby Canine Kidney (MDCK) cells, butaprost (50 μM; 24 hours) decreases TGF-β-induced fibronectin (FN) production, Smad2 phosphorylation, and epithelial-mesenchymal transition[2].
|
---|---|
ln Vivo |
In mice undergoing surgery for unilateral ureteral obstruction, butaprost (1-4 mg/kg; intraperitoneal injection; twice daily; for 7 days) treatment reduces the development of fibrosis, as evidenced by a decrease in the expression of the α-smooth muscle actin, fibronectin, and collagen 1A1 genes and proteins[2].
|
Cell Assay |
Western Blot Analysis[1]
Cell Types: HEK 293/EBNA cells stably expressing the human EP2 receptor (hEP2-HEK 293/EBNA cells) Tested Concentrations: 1 nM, 10 nM, 100 nM Incubation Duration: 0.5 hrs (hours), 1 hour, 6 hrs (hours), 24 hrs (hours) Experimental Results: Induced about a five-fold upregulation of Nur77 mRNA expression in hEP2-HEK293/EBNA cells. |
Animal Protocol |
Animal/Disease Models: Male C57BL/6 mice (8 weeks of age; 21 g) bearing unilateral ureteral obstruction surgery[2]
Doses: 1 mg/kg, 2 mg/kg, 4 mg/ kg Route of Administration: intraperitoneal (ip) injection; twice (two times) daily; for 7 days Experimental Results: Attenuated the development of fibrosis in mice that underwent unilateral ureteral obstruction surgery. |
References |
[1]. Yanbin Liang, et al. Upregulation of orphan nuclear receptor Nur77 following PGF(2alpha), Bimatoprost, and Butaprost treatments. Essential role of a protein kinase C pathway involved in EP(2) receptor activated Nur77 gene transcription. Br J Pharmacol. 20
[2]. Michael Schou Jensen, et al. Activation of the prostaglandin E 2 EP 2 receptor attenuates renal fibrosis in unilateral ureteral obstructed mice and human kidney slices. Acta Physiol (Oxf). 2019 Sep;227(1):e13291. [3]. K Tani, et al. Design and synthesis of a highly selective EP2-receptor agonist. Bioorg Med Chem Lett. 2001 Aug 6;11(15):2025-8. |
Molecular Formula |
C24H40O5
|
---|---|
Molecular Weight |
408.57
|
CAS # |
69685-22-9
|
Appearance |
Typically exists as solids (or liquids in special cases) at room temperature
|
SMILES |
CCCC1(CCC1)[C@H](C/C=C/[C@@H]2[C@@H](CCCCCCC(=O)OC)C(=O)C[C@H]2O)O
|
HS Tariff Code |
2934.99.9001
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80: Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 :Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400  (Please use freshly prepared in vivo formulations for optimal results.) |
---|
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 2.4476 mL | 12.2378 mL | 24.4756 mL | |
5 mM | 0.4895 mL | 2.4476 mL | 4.8951 mL | |
10 mM | 0.2448 mL | 1.2238 mL | 2.4476 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.